Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.62 |
| ▸ | PDPK1 | O15530 | 9/20 | 0.58 |
| ▸ | AURKA | O14965 | 3/20 | 0.58 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.58 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.58 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.58 |
| ▸ | SGK1 | O00141 | 5/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.46 |
| ▸ | CHUK | O15111 | 1/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24137787 | 0.83 | JAK2 (0.61) | JAK2PDPK1AURKATGFBR1AURKB | |
| SCHEMBL24137540 | 0.81 | JAK2 (0.58) | JAK2PDPK1AURKATGFBR1AURKB | |
| SCHEMBL12907241 | 0.78 | JAK2 (1.00) | JAK2PDPK1AURKATGFBR1AURKB | |
| SCHEMBL3361070 | 0.78 | JAK2 (1.00) | JAK2PDPK1AURKATGFBR1AURKB | |
| SCHEMBL30338305 | 0.77 | MAPK10 (0.69) | JAK2PDPK1AURKATGFBR1AURKB | |
| SCHEMBL25933252 | 0.77 | JAK2 (0.52) | JAK2PDPK1AURKATGFBR1AURKB | |
| SCHEMBL24137917 | 0.76 | MKNK1 (0.58) | JAK2PDPK1AURKATGFBR1AURKB | |
| SCHEMBL24137797 | 0.76 | JAK2 (0.51) | JAK2PDPK1AURKATGFBR1AURKB | |
| SCHEMBL22191685 | 0.76 | RET (0.51) | AURKAAURKBMKNK2CDK2KDR | |
| SCHEMBL24137725 | 0.74 | JAK2 (0.59) | JAK2PDPK1AURKATGFBR1AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-07-27 | — | — | US | disclosed |
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | PACSIN2, MAP3K20, PHKG1 | JAK2 228/4885PDPK1 123/4885AURKA 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.